CXCL9 and metastatic melanoma: In metastatic melanoma patients, biopsies were collected before and post-treatment with ipilimumab, an antibody targeting CTLA-4, and as expected, patients displaying higher immune-related gene expression (including CXCL9, 10 and 11) at baseline had a higher total infiltration of lymphocytes and a better response to the ICB.